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Aim To retrospectively assess if the modified lung function 
score (LFS) and/or its components, forced expiratory vol-
ume within the first second (FEV1) and diffusion capacity 
for carbon monoxide corrected for hemoglobin level (cDL-
CO), predict overall survival (OS) and chronic graft-vs-host-
disease (cGvHD).
Methods We evaluated 241 patients receiving allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) at the 
University of Regensburg Transplant Center between June 
1998 and July 2005 in relation to their LFS, FEV1 and cDLCO, 
before and after HSCT.
Results Decreased OS after allo-HSCT was related to de-
creased pre-transplantation values of FEV1<60% (P = 0.040), 
cDLCO<50% of predicted value (P = 0.025), and LFS≥III 
(P = 0.037). It was also related to decreased FEV1 at 3 and 12 
months after HSCT (P < 0.001 and P = 0.001, respectively) 
and increased LFS at 3 and 12 months after HSCT (P = 0.028 
and P = 0.002, respectively), but not to changes of cDLCO. A 
higher incidence of cGvHD was related to decreased FEV1 
at 6, 12, and 18 months (P = 0.069, P = 0.054, and P = 0.009, 
respectively) and increased LFS at 12 months (P = 0.002), 
but not to changes in cDLCO.
Conclusions OS was related to both LFS and FEV1, but 
cGvHD had a stronger relation to FEV1 than to cDLCO or 
LFS. FEV1 alone offered more information on the outcome 
after allo-HSCT than LFS or cDLCO, suggesting limited val-
ue of LFS for the patients’ assessment after allo-HSCT.
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Pulmonary complications significantly contribute to late-
onset morbidity and mortality after allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT). Patients with 
pulmonary dysfunction surviving longer than 2 years had 
a 15.1-fold increased risk of late mortality than the general 
population (1). Late onset non-infectious pulmonary com-
plications can present in different forms, such as restric-
tive changes on pulmonary function testing (PFT) only, 
late interstitial pneumonitis (IP), cryptogenic organizing 
pneumonia (COP), airflow obstruction detected by PFT 
only, or bronchiolitis obliterans (BO)/bronchiolitis obliter-
ans syndrome (BOS). Both, restrictive or obstructive chang-
es can occur isolated or in combination (2-5). Although 
the only currently accepted form of chronic graft-vs-host-
disease (cGvHD) of the lung is BO/BOS, it seems that all 
forms can occur associated with cGvHD and, although 
not pathophysiologically fully understood, may reflect po-
tential overlapping forms or different phenotypes of pul-
monary cGvHD (2-11). BO/BOS is presumably the most 
detrimental form characterized by frequent non-respon-
siveness to treatment, progressive clinical course, and ir-
reversibility, all of which contributes to its high morbidity 
and mortality (12,13).
cGvHD is a major complication in long-term survivors after 
allo-HSCT (1,14,15), with a 6-year incidence of up to 61% in 
patients receiving peripheral blood stem cells (PBSC) (15) 
and with relevant impact on the quality of life in many pa-
tients (16-18).
The lung function score (LFS) combines the forced expi-
ratory volume in the first second (FEV1) and the diffusion 
capacity of the lung for carbon monoxide corrected for 
hemoglobin level (cDLCO) in an equally distributed man-
ner. The LFS was first proposed by Parimon et al (19) as an 
approach to correlate PFT results prior to allo-HSCT with 
the clinical outcome. Later it was modified into more pre-
cise subcategories by the National Institute of Health (NIH) 
Consensus Development Project on the criteria for clinical 
trials in cGvHD (Table 1) and suggested as a score to quan-
tify pulmonary cGvHD and evaluate the effect of cGvHD 
treatment (20). In our clinical practice, we have seen cDL-
CO decreasing already after induction of treatment and 
remaining low for several months after allo-HSCT without 
obvious impact on the outcome. Therefore the aim of this 
study was to evaluate the association of pre- and post-
HSCT LFS, defined according to the NIH consensus devel-
opment project definition (20), and the LFS constituting 
parameters cDLCO and FEV1 individually, with overall sur-
vival (OS) and development of cGvHD after allo-HSCT.
PatiEnt CHaRaCtERiStiCS anD mEtHoDS
Patient characteristics
This retrospective single-center study included 241 out of 
247 adult patients of Caucasian origin who received allo-
HSCT at the University of Regensburg Medical Center, Re-
gensburg, Germany between June 1998 and July 2005; 6 
patients were excluded due to missing data on pulmonary 
function before allo-HSCT. The median follow-up was 711 
days (range, 22-3091 days) and the last day of recording 
data was March 31, 2007. Mean age was 44.5 years, 39% of 
patients were female and 69% male, 48% had a related and 
52% an unrelated donor, 46% of patients had Eastern Co-
operative Oncology Group (ECOG) index 0, 46% had ECOG 
index 1, and only 2% had ECOG index 2.
Prior to transplant, patients gave informed consent on the 
use of patient- and treatment-related information for ret-
rospective analyses and publication. Standard myeloab-
lative conditioning regimens consisted mainly of 8-12 Gy 
fractionated total body irradiation followed by high dose 
cyclophosphamide +/− fludarabine or classic busulfan/cy-
clophosphamide, whereas reduced intensity conditioning 
(RIC) consisted mainly of the FBM (fludarabine/BCNU/mel-
phalan) regimen (21). T-cell depletion for unrelated donor 
HSCT was performed by serotherapy with antithymocyte 
globulin (ATG) in 147 patients, with alemtuzumab in 4 pa-
tients, and with ex vivo selection of donor CD34+ cells in 
taBlE 1. lung function score (lFS) according to Pavletic et al (20)*
FEV1 in % of predicted cDlCo in % of predicted Score Σ score (FEV1 + cDlCo) lFS
>80 >80 1 Normal  2 I
70-79 70-79 2 Mild decrease  3 - 5 II
60-69 60-69 3 Moderate decrease  6 - 9 III
50-59 50-59 4 Severe decrease 10 - 12 IV
40-49 40-49 5
<40 <40 6
*FEV1 – forced expiratory volume in the first second; cDlCo –.diffusion capacity of the lung for carbon monoxide corrected for hemoglobin level.
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24 patients. The severity of acute GvHD was graded from 0 
to 4 using the Glucksberg scale (22). cGVHD was classified 
into no, limited, and extensive disease according to Shul-
man et al (23) and grouped by the presence or absence of 
cGvHD (Table 2).
PFT was scheduled before allo-HSCT and 3, 6, 9, and 12 
months after transplant. Thereafter, patients were sup-
posed to return to the center at 6-month intervals for 
follow-up or at shorter intervals if clinical complications 
were present. PFT was performed in our center accord-
ing to the guidelines of the European Respiratory Society 
using the MasterScreen Body (Viasys Health Care, Würz-
burg, Germany) including spirometry, body plethysmog-
raphy, and diffusion capacity measurements using the 
single breath method. The data were digitally stored. The 
following variables were considered longitudinally: vital 
capacity (VC), total lung capacity (TLC), FEV1, FEV1/VC-
ratio, and the diffusion capacity using the single-breath 
method (DLCO). This study focused only on FEV1 and cDL-
CO. Because LFS is composed of percentage of predicted 
values of cDLCO and FEV1, we also used percentages of 
predicted values for better comparability. Predicted val-





acute leukemia, myelodysplastic syndrome 127 (53)
chronic myeloid leukemia 25 (10)
Hodgkin´s disease 6 (3)
non-Hodgkin lymphoma 45 (19)
multiple myeloma 18 (7)
myeloproliferative disease 10 (4)
other 10 (4)
Stage of disease at allogeneic hematopoietic 
















matched related donor 115 (48)









Cytomegaly virus reactivation risk
negative/negative 93 (39)
donor negative/recipient positive 41 (17)




reduced intensity conditioning 126 (52)
myeloablative 115 (48)
t-cell depletion (with antithymocyte globulin, 










peripheral blood stem cells 193 (80)
bone marrow 48 (20)
acute graft-vs-host-disease (GvHD)
no or stage 1 110 (46)





*mean patient age: 44.5 years (17-68 years); mean donor age: 40.2 
years (13-67 years).
taBlE 2. Patient characteristics regarding allo-HSCt and disease. Stage of disease is defined as 1 for first complete remission of acute 
leukemia or non-Hodgkin lymphoma or chronic phase of chronic myeloid leukemia)*
Characteristics n = 241 (%)
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ues were calculated according to Cotes et al and Quanjer 
et al (24,25) and DLCO was adjusted to the hemoglobin 
level (cDLCO).
Statistical analysis
All statistical analyses were performed using SPSS, 23.0 
(IBM, Corporation, Armonk, NY, USA). Χ2 test was used to 
compare two categorical variables and analysis of vari-
ance was used to compare multiple categorical variables. 
Brown-Forsythe test was used if homoscedasticity was 
not assumed. Post-hoc analysis was done with the Scheffé 
procedure or, in case of unequal distribution of variances, 
with Dunnett-T3 test. For description of the time course 
of pulmonary function parameters matched-pair analysis 
was used. For OS, actuarial curves were obtained by the 
Kaplan-Meier analysis and compared using the log-rank 
test. To assess the relation between LFS, cDLCO, and FEV1 
and the development of cGvHD, Cox-regression analy-
sis was used. Stem cell source, GvHD prophylaxis, acute 
GvHD, related or unrelated donor, female donor into male 
recipient, reduced intensity or myeloablative condition-
ing, busulfan in the conditioning regimen, ECOG before 
HSCT, CMV-reactivation risk, thoracic radiation, total body 
irradiation, history of smoking, age over 40 years, and T-
cell depletion were tested in a forward and backward 
analysis as covariates. As acute GvHD (none or grade 1 vs 
grade 2-4: hazard ratio [HR] 1.855 (1.204-2.857), P = 0.005) 
and reduced intensity vs myeloablative conditioning (HR 
1.584 [1.027-2.441], P = 0.037) had significant influence on 
the development of cGvHD, these covariates were includ-
ed in the final analysis. In all analyses a two-sided signifi-
cance level of α = 0.050 was considered significant.
RESultS
time course of FEV1, cDlCo, and lFS after allo-HSCt
Changes over time of cDLCO, FEV1, and LFS in surviving pa-
tients are demonstrated in Figure 1. Pre-allo HSCT cDLCO 
values significantly correlated with cDLCO up to 4 years af-
ter allo-HSCT, pre-allo HSCT FEV1 values significantly corre-
lated with FEV1 up to 6 years after allo-HSCT, and pre-HSCT 
LFS significantly correlated with LFS values up to 4 years 
after allo-HSCT (data not shown).
cDLCO and FEV1 showed a weak but significant positive 
correlation before allo-HSCT (r = 0.4421; Figure 2A), at 3 
(r = 0.3773; Figure 2B), at 6 (r = 0.4016; Figure 2C) and at 12 
months after allo-HSCT (r = 0.3135; Figure 2D), and chang-
es in cDLCO more than those in FEV1 contributed to an in-
crease in LFS.
FiGuRE 1. time course of diffusion capacity of the lung for 
carbon monoxide corrected for hemoglobin level (cDlCo) 
(A), forced expiratory volume in the first second (FEV1) (B) 
and lung function score (lFS) (C). Values represent the mean 
of pulmonary function testing (PFt) result of all patients 
measured at a given time point. For FEV1 and cDlCo, both 
percentage of predicted values (solid triangle) and percentage 
of patient-specific pre-allo-hematopoietic stem cell transplan-
tation (HSCt) value (hollow triangle) are shown. Percentages 
of predicted values (solid triangle) were used to calculate lFS. 
tables below indicate the number of patients for whom PFt 
was performed at a given time point.
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influence of pre- and post-transplantation pulmonary 
function on overall survival
We next determined the influence of pre-transplantation 
PFT parameters on clinical outcome. Pre-HSCT cDLCO 
showed no linear relation with OS (Figure 3A). Yet, pa-
tients with cDLCO<50% of predicted value had signifi-
cantly lower OS than patients with cDLCO≥50% (20.0% 
vs 41.1%, P = 0.025, Figure 3C). After we classified pre-
HSCT FEV1 values by 10% increments, a trend but not a 
significant impact of decreased FEV1 on OS was observed 
(P = 0.052, Figure 3B). However, patients with pre-HSCT 
FEV1<60% of predicted value had significantly shorter 
OS than patients with pre-HSCT FEV1≥60% (0% vs 38.4%, 
P = 0.040, Figure 3D).
After allo-HSCT, no relation between OS and cDLCO was 
seen at 3 (P = 0.187; Figure 3E) and 12 months (P = 0.090; 
Figure 3G). In contrast, decreased FEV1 demonstrated a sig-
nificant relation with OS at both time points (both P < 0.001, 
Figure 3F+H).
Although no significant relation was found between pre-
HSCT LFS and OS, shorter OS was observed with an increase 
in LFS grade, but the trend was not significant (5-year OS 
LFS I: 41.2%; LSF II: 36.8%; LFS III: 26.7%, P = 0.191, Figure 4A), 
suggesting LFS≥III can be considered a predictive thresh-
old of shorter survival. Patients with a pre-HSCT LFS III/IV 
had a shorter overall survival than patients with pre-HSCT 
LFS I/II (307 vs 918 days respectively, P = 0.069, Figure 4B). 
OS was significantly shorter in patients with a baseline LFS 
III compared to patients with LFS I (median OS 307 vs 2208 
days, P = 0.037, not shown).
After HSCT, increased LFS showed strong influence on OS 
at both 3 (P = 0.028; Figure 4C) and 12 months (P = 0.002; 
Figure 4E), confirming LFS III/IV as a critical threshold at ei-
ther time point (3 months: P = 0.005; Figure 4D; 12 months: 
P = 0.001; Figure 4F).
Relationship between cGvHD and lFS
LFS has been proposed as a parameter in the assessment 
of chronic pulmonary GvHD (20). Therefore, we tested 
whether LFS values predicted the occurrence of cGvHD in 
our patient cohort. Of the 241 patients, 109 (45%) devel-
oped cGvHD, 14.7% until day +120, 25% until day +142, 
50% until day +180, 75% until day +229, and 87% after 
one year (median time of onset: 180 days, range 94-1912 
days). As mentioned above, acute GvHD (none or grade 1 
FiGuRE 2. linear regression curves of forced expiratory vol-
ume in the first second (FEV1) and carbon monoxide corrected 
for hemoglobin level (cDlCo) in percentages of predicted 
value before allo-hematopoietic stem cell transplantation 
(HSCt) (A), P < 0.001), and 3 (B), P < 0.001), 6 (C), P < 0.001), and 
12 months (D), P < 0.001) after it.
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FiGuRE 3. overall survival in relation to diffusion capacitiy for carbon monoxide corrected for hemoglobin level (cDlCo) and forced 
expiratory volume in the first second (FEV1) values before allogeneic hematopoietic stem cell transplantation (allo-HSCt) (A-D), and 
at 3 and 12 months (E-H) after allo-HSCt. Pulmonary function testing (PFt) intervals for cDlCo and FEV1 are grouped as follows: 1: 
≥80%; 2: 70%-80%; 3: 60%-70%; 4: 50%-60%; 5: <50% of predictive value in panel (A), (B), and E-H; in panel C, cDlCo is divided in 
≥50% vs <50%; and in panel (D), FEV1 is grouped in ≥60% vs <60% of predicted value. linear P values obtained using log rank test 
are: panel (A) (P = 0.351), panel (B) (P = 0.025), panel (E) (P = 0.187), panel (G) (P = 0.090), panel (C) (P = 0.052), panel (D) (P = 0.040), 
panel (F) (P < 0.001), and (H) (P < 0.001).
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vs grade 2-4: HR 1.855 (1.204-2.857), P = 0.005) and reduced 
intensity vs myeloablative conditioning (HR 1.584 [1.027-
2.441], P = 0.037) had significant influence on the develop-
ment of cGvHD in the unadjusted model, resulting in the 
inclusion of these covariates in the final analysis.
Three months after HSCT, we evaluated cDLCO in 122 pa-
tients and FEV1 in 125 patients. Out of these, 69 and 72 pa-
tients, respectively, developed cGvHD. Neither in the ad-
justed nor in the unadjusted Cox-regression model LFS, 
cDLCO, and FEV1 were related to the development of 
cGvHD (not shown).
Six months after allo-HSCT, we evaluated cDLCO in 122 
patients and FEV1 in 126 patients. Out of these, 74 and 75 
patients, respectively, developed cGvHD. Unadjusted Cox-
regression model showed that decreased FEV1 was signifi-
cantly related to the development of cGvHD (P = 0.030, not 
shown), while changes in cDLCO and LFS were not. After 
adjustment for acute GvHD and conditioning regimen (re-
FiGuRE 4. overall survival in relation to lung function score (lFS) values before allogeneic hematopoietic stem cell transplantation 
(allo-HSCt) (A, B), at 3 (C, D) and at 12 months (E, F) after allo-HSCt. lFS grades i-iV as defined in table 1 (A, C, E) and grouped into i 
and ii vs iii and iV in B, D and (F). linear P values obtained using log rank test are panel (A) (P = 0.191), panel (B) (P = 0.069), panel (C) 
(P = 0.028), panel (E) (P = 0.002), panel (D) (P = 0.005), and panel (F) (P = 0.001).
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duced intensity vs myeloablative), there was still a relation 
between decreased FEV1 and development of cGvHD but 
it was not significant anymore (P = 0.069, Table 3), which 
might be due to very small number of patients with de-
creased FEV1.
One year after allo-HSCT, cDLCO was evaluated in 111 and 
FEV1 in 116 patients, out of these 71 and 72, respectively, 
developed cGvHD. Both adjusted and unadjusted Cox-re-
gression model showed a significant influence of LFS on 
the development of cGvHD (Table 3, P = 0.002 for both). In 
the unadjusted model decreased FEV1 showed a trend to-
ward a relation with the occurrence of cGvHD (P = 0.107, 
not shown), which became almost significant in the ad-
justed model (Table 3; P = 0.054). There was no relation be-
tween cDLCO and cGVHD development.
Eighteen months after allo-HSCT, cDLCO was evaluated in 
104 and FEV1 in 106 patients. Out of these, 67 patients de-
veloped cGvHD at the time of PFT or subsequently. Only 
FEV1 showed a significant influence on cGvHD in the un-
adjusted and adjusted model (not shown, P = 0.036 and 
0.009. respectively).
Decrease in FEV1 after day +90 and incidence of cGvHD
We further determined the difference in FEV1 at day +180 
and day +365 compared to day +90, as well as at day +180 
compared to day +365, and considered a 10% decrease as 
relevant. A decrease of more than 10% from day +90 to day 
+180 was seen in 19 out of 83 patients in whom PFT was 
done; from day +90 to day +365 in 23 of 87 patients; and 
from +180 and day +365 in 16 of 89 patients.
The incidence of treatment related mortality did not sig-
nificantly differ between the patients with a relevant FEV1 
decline and the patients with stable or increased FEV1 be-
tween day +90 and day +180 as well as between day +90 
and day +365, but it increased in patients with a FEV1 de-
cline between day +180 to day +365 from 5.5 to 25% (Ta-
ble 4). In addition, 15 patients with a decrease in FEV1 be-
tween day +180 and day +365 had a higher incidence of 
taBlE 3. Cox-regression analysis for the risk of developing chronic graft vs host disease (cGvHD) depending on pulmonary function 
parameters at day +180 and day +365. the adjusted model included acute GvHD and reduced intensity vs myeloablative condition-
ing as covariates*
Day +180 Day +365
Parameter n adjusted HR (95% Ci) P n adjusted HR (95% Ci) P
lFS grade
I 33 referent 28 referent
II 70 0.779 (0.457-1.330) 0.360 69 0.970 (0.546-1.721) 0.916
III 19 0.788 (0.370-1.677) 0.536 13 3.313 (1.547-7.095) 0.002
IV 0 1 3.540 (0.451-27.804) 0.229
trend 0.640 trend 0.002
FEV1
>80% 103 referent 91 referent
70%-80% 15 0.852 (0.407-1.784) 0.671 15 1.418 (0.719-2.796) 0.313
60%-70% 6 1.419 (0.432-4.661) 0.564 7 3.029 (1.170-7.844) 0.022
50%-60% 1 27.423 (2.783-270.184) 0.005 0
40%-50% 1 0 (0-8.66x10^213) 0.970 3 2.605 (0.775-8.761) 0.122
<40% 0 0
trend 0.069 trend 0.054
cDlCo
>80% 34 referent 30 referent
70%-80% 24 0.701 (0.349-1.407) 0.317 29 0.885 (0.453-1.728) 0.720
60%-70% 34 0.742 (0.406-1.356) 0.333 30 0.963 (0.497-1.867) 0.911
50%-60% 20 0.545 (0.249-1.194) 0.129 17 1.568 (0.722-3.403) 0.256
40%-50% 8 1.346 (0.507-3.576) 0.551 4 2.867 (0.952-8.629) 0.061
<40% 2 1.604 (0.373-6.901) 0.525 1 3.000 (0.382-23.581) 0.296
trend 0.439 trend 0.241
*HR – hazard ratio; lFS – lung function score; FEV1 – forced expiratory volume in the first second; cDlCo –.diffusion capacity of the lung for carbon 
monoxide corrected for hemoglobin level.
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cGvHD (93.8 vs 53.4%), pulmonary GvHD (56.3 vs 11.0%), 
and a lower OS (56.3 vs 82.2%) than 39 patients with stable 
FEV1 in this period. In contrast, OS did not differ between 
patients with or without FEV1 decline between day +90 
and day +180 or day +90 and day +365. The incidence of 
pulmonary cGvHD did not differ in patients with or with-
out FEV1 decline between day +90 and day +180, where-
as the incidence of lung disease in patients with a decline 
of FEV1>10% between day +90 and day +365 was 26.1% 
compared to 9.4% only in patients with stable FEV1. The 
incidence of cGvHD irrespective of specific organ mani-
festations did not significantly differ (47.4% vs 59.5% day 
+90 until +180; 65.2% vs 56.3% day +90 until day +365) be-
tween patients with a FEV1 decline and those with stable 
FEV1 (Table 4).
DiSCuSSion
A promising approach to improve the understanding 
and treatment of cGvHD was the NIH Consensus Devel-
opment Project on criteria for clinical trials in cGvHD. One 
goal of this project was to improve the clinical assessment 
of pulmonary cGvHD by proposing LFS as a grading score 
for pulmonary cGvHD (20). In the new diagnostic and re-
sponse criteria of the National Institutes of Health Consen-
sus Development Project, the lung function score (26,27) is 
no longer recommended and FEV1 as single parameter to 
assess GvHD of the lung is suggested (27), which confirms 
our finding that cDLCO has no relation to the development 
of cGvHD.
In our study, overall survival was related to FEV1 and LFS. 
Pre-HSCT FEV1 showed a higher influence on overall sur-
vival than LFS and cDLCO. FEV1<60% and cDLCO<50% 
were associated with inferior survival, consistent with prior 
reports (28). Combining pre-HSCT cDLCO with FEV1 may 
translate into better ability to identify groups at increased 
risk for treatment-related mortality, but this is not sup-
ported by our data.
Parimon et al (19) demonstrated a stronger relation be-
tween OS and a differently defined pre-HSCT LFS in a very 
large patient cohort. This discrepancy might be explained 
by the smaller number of patients in our study and differ-
ences in LFS categorization (in the study by Parimon et al 
FEV1 and cDLCO where scored with 1 for >80%, 2 for 70%-
80%, 3 for 60%-70%, and 4 for <60%, composed in a LFS 
grade of I for 2, II for 3-4, III for 5-6 and IV for 7-8 points).
After allo-HSCT, both decreased FEV1 and increased LFS 
levels were associated with shorter OS, suggesting that 
both FEV1 and LFS are useful parameters in assessing the 
impact of pulmonary function loss after allo-HSCT on 
clinical outcome. Again, while it seems reasonable to hy-
pothesize that the LFS has a higher clinical value com-
pared to the use of FEV1 alone and this might result from 
combining the LFS constituting compounds FEV1 and 
cDLCO, this was not shown in our study. According to the 
current guidelines of the ATS/ERS taskforce (29), FEV1 can 
be used to measure the severity of obstructive and re-
strictive changes in pulmonary function, as either corre-
sponds to a decrease in FEV1. Pulmonary damage due to 
different patterns of pulmonary disease will be merged 
together within the LFS: Airflow obstruction is a common 
complication after allo-HSCT (30,31), and in some cases 
evolves from/to BO (32-34); restrictive changes, accom-
panied by a reduced FEV1, have been frequently report-
ed (10,31,32,35-37); and a reduced cDLCO has been ob-
served in many patients already prior to allo-HSCT, often 
followed by a temporary decline and by a partial recov-
ery after transplantation (28,35,38). In addition, decreased 
cDLCO is found in numerous pulmonary complications 
following allo-HSCT, not only including late onset non-
infectious lung injury, but also early complications such 
as clinical or subclinical alveolitis and interstitial pneu-
monitis, pulmonary hemorrhage, engraftment syndrome 
or pulmonary vascular disease, and presents as reversible 
pulmonary toxicity secondary to conditioning regimens 
(4,7,29,36,39-41).
taBlE 4. incidence of chronic graft vs host disease (cGvHD) overall, cGvHD of the lung, treatment related mortality (tRm), and overall 
survival (oS) in patients with a decline of FEV1 from day +90 to day +180 or to day +365, or from day +180 to day +365, of more than 
10% compared to patients with no change or a decrease of less than 10%
time period FEV1 decline >10% cGvHD % (n) cGvHD lung % (n) tRm % (n) oS % (n)
Day +90 – day +180 no 59.5 (44) 16.2 (12) 12.2 (9) 64.9 (48)
yes 47.4 (9) 15.8 (3) 10.5 (2) 73.7 (14)
Day +90 – day +365 no 56.3 (36)  9.4 (6)  6.3 (4) 84.4 (54)
yes 65.2 (15) 26.1 (6)  8.7 (2) 78.3 (18)
Day +180 – day +365 no 53.4 (39) 11.0 (8)  5.5 (1) 82.2 (60)
yes 93.8 (15) 56.3 (9) 25.0 (4) 56.3 (9)
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Consistent with the study by Walter et al (42), we found 
a significant association of FEV1 with cGvHD at 6 and 18 
months and a strong trend at 12 months after allo-HSCT. 
Furthermore, the incidence of cGvHD was associated with 
a decrease of more than 10% FEV1 at day +365, especially 
between day +180 and day +365 and resulted in elevated 
treatment-related mortality and reduced survival. One year 
after allo-HSCT we also showed a significant relation of LFS 
with cGvHD. We also showed that cDLCO<50% potential-
ly contributed to the LFS interrelation with cGvHD, but it 
alone was not related to cGvHD.
In contrast to our study, which showed no significant as-
sociation between impaired FEV1, cDLCO, and LFS values 
at day +90 and overall development of cGvHD, Walter et al 
(42) demonstrated a significant association of high LFS at 
day +80 with the development of cGvHD within one year 
after HSCT, attributing their observation mostly to a de-
crease in FEV1 rather than cDLCO. The different results may 
be explained by a different composition of the patient-
specific LFS values, as in our cohort only 5% of patients had 
a FEV1 below 70% compared to 11% in the study by Walter 
et al. Also, a transitional decrease in lung function deter-
mined by PFT can occur in this time period post HSCT due 
to non-GvHD causes (38,39,43). The relatively early drop 
in pulmonary function, mainly reflected by a decrease in 
cDLCO, might be attributed to infectious complication or 
cytokine-mediated effects after allo-HSCT (4,7,44,45). Wal-
ter et al further restricted their data to patients developing 
cGvHD within one year after HSCT, whereas in our study 
no such time limit was set. Patients developing cGvHD at 
later time points can have normal LFS at day +90, there-
fore showing no relation between day +90 LFS and cGvHD, 
as observed in our cohort. Furthermore our study popula-
tion is smaller than the one evaluated by Walter et al (42), 
therefore our study is potentially underpowered to detect 
a (minor) predictive role of LFS at 3 months for survival and 
for Cox-regression models with up to 5 different catego-
ries as assumed by inconsistent hazard ratios for FEV1 at 12 
months as well as for FEV1, cDLCO, and LFS at 3 months.
Another limitation of our study was that since only pa-
tients transplanted until 2005 were included in the analy-
sis, severity grading of cGVHD was not performed accord-
ing to the NIH consensus (27,46). Conditioning regimens 
as well as GvHD prophylaxis and treatment approaches 
may differ between centers, therefore possibly limiting the 
results of our study. However, up to now calcineurin inhib-
itor plus methotrexate have remained the gold standard 
and response rates for second line treatment in steroid re-
fractory GvHD rates are similar across different approaches 
and no definite recommendation as to which is superior 
can be given.
Also, we compared the lung function with overall cGvHD 
rather than with lung GvHD. In our cohort of 241 patients, 
only 24 had symptomatic lung GvHD, therefore statistical 
analysis has to be interpreted with caution due to small pa-
tient number. During the follow-up, FEV1 decreased slight-
ly, which might be due to long-term toxicity, but also due 
to mild cGvHD not clinically affecting the lungs or cGVHD 
resulting in subtle changes within the lung.
This study showed that FEV1 as a single parameter had a 
strong association with both OS and cGvHD at most time 
points before and after allo-HSCT. However cDLCO did not 
show such an association, which gives only limited sup-
port for the application of the LFS as defined by the NIH 
Consensus Project on cGvHD (20) with respect to its pre-
dictive value on transplantation outcome and its relation 
with cGvHD. Therefore, prospective trials investigating the 
value of LFS combining FEV1 and cDLCO as a predictor 
of treatment response are needed. The presented results 
further allow to formulate clinically relevant implications, 
such as a) a regular screening of FEV1 after allo-HSCT iden-
tifies patients with lung manifestations of cGvHD, while 
cDLCO appears to be only of clinical relevance if <50% of 
the predicted normal value, b) the assessment of FEV1 at 
day +90 is recommended as baseline to assess the toxic-
ity of the conditioning regimen, but is unlikely to detect 
changes already related to pulmonary cGvHD, c) the ma-
jority of patients developing pulmonary cGvHD show a 
decline of FEV1 between day +180 and day +365 after allo-
HSCT and d) reduction of FEV1>10% compared to baseline 
is associated with increased morbidity and mortality. Ad-
ditionally, novel parameters like acinar airways ventilation 
heterogeneity and lung clearance index (47) might evolve 
as markers for early diagnosis of pulmonary involvement in 
cGvHD, and their evaluation alone or in combination with 
LFS or FEV1 is warranted.
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